The edge of understandable, page-7

WW and travelbug, I suspect you are both right.

I understand that targeted drugs such as Gleevec are more effective against blood cancers than solid tumours found in breast or lung cancer, which literally build walls of tissue to protect themselves. That would suggest that there would be fewer hurdles for blood cancer than breast cancer.

Also, the blood cancers mentioned - Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia and Multiple Myeloma- all qualify as orphan diseases, meaning there’s monetary/development/regulatory/ market exclusivity advantages there which are very attractive to pharma. Imo.